

3 November 2011

## Approval of proposal to amend the terms of listing for efavirenz (Stocrin)

PHARMAC is pleased to announce the approval of an agreement with Merck Sharp and Dohme (New Zealand) Limited (MSD) for efavirenz (Stocrin). This was the subject of a consultation letter dated 22 September 2011. In summary, the effect of the decision is that:

- From 1 January 2012, Stocrin will remain listed in Section B of the Pharmaceutical Schedule at the following prices and subsidies (ex-manufacturer, excluding GST):

Chemical	Presentation	Brand	Pack size	Price and subsidy
Efavirenz	50 mg tablet	Stocrin <sup>S29</sup>	30	\$158.33
Efavirenz	200 mg tablet	Stocrin	90	\$474.99
Efavirenz	600 mg tablet	Stocrin	30	\$474.99

- Stocrin will remain funded in the community subject to the Special Authority currently applying to all antiretrovirals;
- From 1 January 2012 a rebate will apply to all community dispensings of Stocrin reducing the net price to the funder; and
- Stocrin will have subsidy and delisting protection until subsidy and delisting protection until 30 June 2015.

### Feedback received

All consultation responses received by 6 October 2011 were considered in their entirety in making a decision on the proposed changes. One response was received and it was supportive of the proposal.

### More information

If you have any questions about this decision, you can call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.